Johnson & Johnson ordered to pay $8bn in Risperdal case
A jury has said that Johnson & Johnson must pay $8 billion in the case over male breast growth linked to Risperdal.
List view / Grid view
A jury has said that Johnson & Johnson must pay $8 billion in the case over male breast growth linked to Risperdal.
Research has found that North America had the most strategic partnerships in the pharma industry from 2014 to 2019.
Despite plans to lower drug prices in the US, political divisions have muddied the waters. This article examines the efforts made by those involved and the possibilities of their success.
The global pharma contract development and manufacturing organisation (CDMO) outsourcing market is predicted to grow.
The UK Competition and Markets Authority has alleged that Aspen paid two other pharmaceutical companies to ensure they were the only supplier of a drug to the NHS.
The government has announced new measures to prevent parallel exporting to ease the supply chain, in an effort to reduce medicine shortages.
Johnson & Johnson have reached a settlement with two Ohio counties over its role in the opioid crisis, removing the company from the trial due to begin later this month.
A survey of pharmacists has discovered that UK pharmacies experienced shortages across all 36 medicine categories in the last six months.
Research has found that the pharmaceutical industry in India must encourage innovation in order to keep up with the growth of the sector.
Increasing demand for convenient drug delivery, as well as an increase in diseases such as diabetes, has fuelled the global injectable drug delivery market.
King Pharmaceuticals Limited and Alissa Healthcare Research Limited have admitted to sharing information to keep drug prices up.
The British Pharmacopoeia and United States Pharmacopeia partnership is to be formalised to strengthen the quality of medicines and public health.
A treatment for anaemia associated with chronic kidney disease in dialysis patients has been approved in Japan.
The government of an Indian province and a US company have teamed together in an initiative to deliver medications to remote regions using drones, which should begin next year.
A new report has shown that trial evidence alone is not enough when approving new cancer drugs and that an assessment of that evidence is also needed.